Its revenue expanded by more than 880% in the third quarter compared to 2019, and the company is firmly profitable. If management can execute on its goal of making genetic screening accessible to everybody, then that could only be the tip of the iceberg. Stock Advisor launched in February of 2002. Some of those tests … The number of people diagnosed with cancer is increasing because of a larger, longer-living population, and that suggests the need for genetic screening enabled by gene sequencing is heading higher. Hereditary cancer tests accounted for almost 100% of revenue in 2013; however, they've fallen to about 25% of revenue in 2018 as more tests have been introduced, including GeneSight, a test for determining the best drugs for patients with depression, and prenatal screening tests for genetic disorders. Some are already making good on their potential. Check out Benzinga's best marijuana penny stocks for 2021: updated daily. Between the complexity of the science and the demands of the clinical trials and regulatory approval process, it's also quite risky -- but the rewards can be immense. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. There are about 3 billion base pairs containing instructions necessary for human existence, and there are an estimated 30,000 genes, each responsible for making an average of three proteins. More specifically for our purposes today: Each gene contains a distinct series of nucleotides, molecules that form deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). DNA is the genetic blueprint necessary for building and maintaining organisms, including humans, while RNA is a copy of DNA that's tasked with making proteins necessary for healthy bodies. The report forecasts the market size out to … Seattle Genetics (NASDAQ:SGEN) Market cap: US$26.12 billion. All 7 stocks are included in the portfolio computations. Sales for both of these gene therapies could increase significantly, though, because of trials evaluating earlier use of these therapies in treatment. Sales jumped 117% year over year to $148 million in 2018, and in 2019, it's targeting revenue of $220 million. Celgene's gene therapy program stems from its $9 billion acquisition of Juno Therapeutics in 2018. Adenine (A) pairs with thymine (T), while cytosine (C) pairs with guanine (G). Gene-sequencing companies: These companies market systems to researchers that can be used to sequence genes using short- or long-read technology. That number is expected to grow to 100 million by 2021. So, the real question is: What management will choose to spend the windfall on? In 2018, its sales eclipsed $3.3 billion, up from $2.7 billion in 2017, and in 2019, ongoing growth has management targeting sales of about $3.8 billion. That might change next year if its vaccine is proven effective. Furthermore, Co-Diagnostics is moving quickly to develop new genetic tests that can detect viral mutations for the laboratory research market, ensuring that it will stay relevant through next year and beyond. About 80% of the estimated 350 million people worldwide with rare diseases are caused by a faulty gene, according to nonprofit Global Genes. The ongoing interest in gene sequencing fueled by lower prices and deeper insight into genetic disease has allowed Illumina to deliver 20 consecutive years of revenue growth and capture an estimated 75% market share. Demand for NovaSeq has been robust, reaching $1 billion in shipments in just two years. Cumulative Growth of a $10,000 Investment in Stock Advisor, eliminate the need for a lifetime of transfusions, it paid $2.4 billion to acquire Foundation Medicine, offer low-cost comprehensive genetic screening to everyone, Copyright, Trademark and Patent Information. Novartis' Kymriah is also approved for use in adults with certain blood cancers that fail to respond to other treatment options. Its sales totaled $76 million in 2018, including $28 million in the fourth quarter. Here's what you need to know about the industry, how it's changing, and the top gene-sequencing stocks worth owning. Genetic Testing Companies Step In Privately held companies like 23andMe and Ancestry.com popularized genotyping, a method of looking for genetic differences in a … That led to sharply lower stock prices on Monday in nearly every industry, including genetic testing. Since these companies may wind up competing more aggressively with one another in the future, investors will want to keep close tabs on this market. Agilent Technologies, established in 1999 is one of the world’s leading … But advances in the accuracy, speed, and cost of genetic sequencing have led to breakthroughs that could only be imagined a few years ago -- and that's creating exciting opportunities for researchers and investors alike.Â. Up 1,000% in 2020, Is Co-Diagnostics Stock Still a Buy? DNA — the genetic … If you're interested in investing, the only thing to do at the moment is to watch for clinical trial updates to see how its core project is advancing. Over 250 companies are conducting this research, up from fewer than 70 in 2014. Investors should watch the company's pipeline updates carefully, not to mention its earnings reports. Further investment in expanding its market penetration with these products will help to keep the company's momentum next year and beyond. Genetic testing is soaring, and so are these stocks, writes Michael Brush. Invitae Stock – A Pure-Play on Genetics Testing. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. Gene therapies developed by these biotechnology companies may seek to shut off (or knock down) a gene's production of a gene, sidestep the mutation causing the genetic disease, or edit the gene to restore normal protein production. In 2019, Genomic Health's guidance is for sales to climb another 11% to 14%. Long-read sequencing isn't without its drawbacks, though. Trials are ongoing. Celgene has also licensed rights to two CAR-Ts -- bb2121 and bb21217 -- developed by bluebird bio for use in multiple myeloma, a bone marrow cancer. Nonetheless, in the long-term its older pipeline projects will start to come to fruition. Sarepta Therapeutics (SRPT) Sarepta Therapeutics (NASDAQ:SRPT) isn’t exactly at home in … Plus, its $2.74 million in debt barely holds a candle to its trailing revenue in excess of $135 million. Afterwards, a computer reassembled the results back into their longer sequence using the reference library. Increasingly, researchers are combining short- and long-read sequencing to obtain the most accurate results. Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Its most advanced gene therapy is liso-cel, a CAR-T for the same cancers addressed by Yescarta and Kymriah that was designed to sidestep the dangerous side effects associated with those two drugs, including a life-threatening condition called cytokine release syndrome. Given how many hopes were riding on its coronavirus vaccine candidate, you shouldn't be surprised to see Moderna (NASDAQ:MRNA) on this list. Thermo Fisher Scientific is no slouch, either. Gene editing therapies are only entering phase 1 studies in 2019, but their use to snip away problematic DNA and splice in functional DNA could propel shares higher at related companies, including CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT). Returns as of 01/24/2021. But you can still buy shares of companies for whom genetic screening is more of a specialty, including Myriad Genetics (NASDAQ:MYGN), Genomic Health (NASDAQ:GHDX), Invitae … GENE Stock Alert: 10 Things to Know About Genetic Technologies As Shares Rocket Higher Jan. 21, 2021 at 10:18 a.m. Long-read sequencing machines can produce reads of 15,000 base pairs on average, and up to 100,000 base pairs under ideal circumstances, helping researchers overcome the obstacle that long repeats present to short-read sequencing. Using a blood test, Guardant's solution can identify genetic mutations with similar accuracy to more invasive tissue biopsies obtained via needles. Invitae was spun out of Genomic Health in 2012. However, not all gene-sequencing stocks are likely to be winners. Gilead Sciences acquired Yescarta when it bought Kite Pharma for $11.9 billion in 2017. Many genetics companies spent the year working on the projects that might become their first sources of revenue. Selling coronavirus diagnostic tests is big business, as shown by the 990% rise of Co-Diagnostics (NASDAQ:CODX) this year. There are about 700 gene therapies under development in roughly 1,800 clinical trials, about 500 of which are in the middle or late stages, according to Informa Pharma Intelligence's Trialtrove database. Most gene therapies target cancer, but they're also being developed for cardiovascular disease and infectious disease. Inovio Pharmaceuticals (NASDAQ:INO) grew by 173% this year thanks to its coronavirus vaccine program. How to Invest in Cannabis Stocks. Intellia Therapeutics (NTLA) Intellia Therapeutics (NASDAQ:NTLA) is also working on a … Initially, the project's goal was to sequence the entire human genome by 2005 at a cost of $3 billion. Investors interested in gene therapy may also want to consider Celgene (NASDAQ:CELG), which was recently acquired by Bristol-Myers Squibb (NYSE:BMY); bluebird bio (NASDAQ:BLUE); Roche Holdings (OTC:RHHBY); and Regenxbio (NASDAQ:RGNX). Let's find out. The human genome was first sequenced by the U.S. government's Human Genome Project, which was announced in 1988 and funded by Congress in 1990. Thanks to hot demand for its coronavirus diagnostic products, Fulgent Genetics (NASDAQ:FLGT) grew by 280% in 2020, and its management increased its full-year revenue guidance by $100 million in November. Drug developers: These companies are using discoveries enabled by gene sequencing to overcome genetic mutations contributing to disease. Other … But, its stock may not be able to keep up with the valuations that 2020 built with hype. Whether its first earnings reports in the new year will herald a reckoning is anyone's guess. RNA can be ribosomal RNA (rRNA), which makes a specific protein; messenger RNA (mRNA), which delivers instructions on how to build a protein; or transfer RNA (tRNA), which transports the raw material necessary for making a protein. Genetic screening companies: These companies provide genetic screening services to drug developers, doctors, and patients to inform drug development and treatment decisions.Â, The marketplace for gene-sequencing machines is dominated by Illumina (NASDAQ:ILMN) and Thermo Fisher Scientific (NYSE:TMO), both of which have built up a large installed base of short-read gene-sequencing machines at researchers worldwide. Why Co-Diagnostics Stock Is Getting Clobbered Today, Copyright, Trademark and Patent Information. It also offers genetic testing for a handful of hereditary cancers and … The short-read sequencers used in the human genome project generated about 500 to 800 base pairs per run, so when repeats exceeded that size, gaps were left -- which is why the project was declared complete after 99%, rather than 100%, of the genome was sequenced. A far more diversified company, Thermo Fisher got into the gene-sequencing business with its $13.6 billion acquisition of Life Technologies in 2014. However, technological advances are making long-read sequencing a viable option as well. Regenxbio is also intriguing because of the role it plays in an FDA decision expected in May 2019 for Novartis' Zolgensma, a gene therapy for a condition affecting motor nerve cells known as spinal muscular atrophy, which takes away the ability to walk, eat, or breathe. Zolgensma, formerly AVXS-101, was developed by AveXis, which Novartis acquired last year for $8.7 billion. To spot genetic mutations, researchers must sequence, or screen, a person's genetic material and then compare it to a baseline. In fiscal 2018, Myriad's revenue totaled $773 million. Genetic Technologies Ltd Sponsored ADR (GENE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. In mid-December, it announced that the government had taken an interest in developing a DNA-encoded monoclonal antibody therapy for COVID-19 using the company's technology. It also offers genetic testing for a handful of hereditary cancers and other disorders. Seattle Genetics is first on … Today, that business is reported within the company's life sciences solutions segment. Arcturus Therapeutics (NASDAQ:ARCT) surged nearly 300% in 2020 by advancing its mRNA-based coronavirus vaccine program, which should enter phase 2 of its clinical trials in the first quarter of 2021. Direct-to-consumer (DTC) DNA testing is a fast-growing industry with over 26 million users worldwide. These therapies reengineer T-cells -- a type of white blood cell that's essential to our immune systems -- to spot proteins on the surface of cancer cells, allowing them to find and destroy cells they'd otherwise miss. One of the two CAR-T's that won approval is Gilead Sciences' (NASDAQ:GILD) Yescarta, while the other is Novartis' (NYSE:NVS) Kymriah. Our ability to treat health problems has historically been hamstrung by an incomplete understanding of the role our own genes play in the process. Guardant Health, which had its initial public offering in October 2018, is the most recent of these companies to go public. The human genetic code is massive, so the project fragmented DNA into smaller, more manageable pieces that could be cloned in bacteria in quantities large enough to create a reference library. They also sell consumables that are used each time a gene sequence is done. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn. Short-read technology remains the fastest and cheapest form of gene sequencing, so it's still the most commonly used approach. Globally, Illumina has over 13,000 systems installed, including 600 NovaSeq machines. ... 4 Stocks to Focus On: Genetic testing specialist Fulgent has seen its revenue and bottom line skyrocket. Over 18 million cancer patients were diagnosed worldwide in 2018, and since understanding how genes contribute to disease is critical to better outcomes, each of these genetic screening stocks could have a long runway of success ahead of it. With growth of around 467%, Moderna will likely turn a profit for the first time next year as its vaccines are sold at mass scale. Before diving into the different gene-sequencing stocks we can invest in, it might be helpful to explain the different categories of companies operating in this field. Luxturna restores vision by using a deactivated virus to deliver a normal copy of a missing gene, RPE65, directly to cells in the retina. The acquisition also landed Roche a promising gene therapy for hemophilia A, SPK-8011, which attempts to restore production of a critical missing clotting factor that otherwise leaves patients exposed to the risk of uncontrollable bleeding. Agilent Technologies. Though its candidate isn't as closely watched as several of the other leading contenders, there's a lot riding on its success. Portfolio values are computed using monthly closes for stocks from Alpha Vantage. Drug companies have already launched medicines targeting DNA and RNA, and more of these gene therapies are on the way. The prospect of using our DNA to inform healthcare decisions is so significant that new players are flocking to this emerging industry all the time. For example, long-read makes sense for complex organisms with little reference data, while short-read is best for analysis of DNA fragments. Technological limits at the time made fragmenting and reassembly necessary, but this sequencing approach is unable to sequence complex genes, including those with particularly long repeats of genetic code. Thermo Fisher doesn't break out exactly how much money its sequencers contribute to its top line, but its life sciences revenue increased 9% to $6.27 billion in 2018, accounting for 26% of the company's $24.4 billion in total sales. Gene sequencing is already contributing to the development of better, more targeted, and potentially safer medicines. There's a lot for investors to like, to say the least. Last year, sales were $394 million, up 18%, including U.S. revenue of $335 million ($299 million of which were sales of its Oncotype DX Breast Recurrence Score test). Illumina estimates less than 0.1% of species, 0.02% of humans, and 1% of human variants have been genetically sequenced so far. There's every indication that its vaccine will be a big moneymaker, potentially to the tune of $32 billion in 2021. The news of the award helped major gene editing stocks like CRISPR Therapeutics AG CRSP rise 11.4% on Oct 7, as Charpentier is one of the co-founders of the company. Like Moderna, Inovio's pipeline also has a smattering of lesser-known vaccines in development, none of which garnered the market's attention very much. Studies that could support FDA approval of bb2121 are expected to wrap up in late 2019, but data reported at this writing is compelling -- it's achieved an overall response rate in patients that's north of 90%. A recent clinical update showed that its candidate might not be as protective as the other mRNA vaccines that are already approved for sale. Roche is a player in this field, too -- in 2018, it paid $2.4 billion to acquire Foundation Medicine after the FDA approved Foundation's comprehensive genetic screening test for cancer. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. For example, it's already filed for European approval of LentiGlobin, a gene therapy for transfusion-dependent β-thalassemia, an inherited blood disease that can result in severe anemia. LentiGlobin could eliminate the need for a lifetime of transfusions by inserting a functional human beta-globin gene into the DNA of a patient's blood stem cells. Studies are also evaluating LentiGlobin's potential in sickle cell disease, a life-threatening blood disorder.Â. Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In February 2019, Roche announced it was acquiring Spark Therapeutics for $4.8 billion. Spark won FDA approval for Luxturna, a gene therapy for a rare cause of blindness, in December 2017. Its liquid biopsy is already winning converts. These bacterial artificial chromosome (BAC) clones were then cut into short fragments, or subclones, that could be used in sequencing machines. Learn how to invest in marijuana stocks … Likewise, its vaccine administration device developed with public funding may be key to its future success. If these mutations cause abnormal or inadequate protein production, it can result in one of over 6,000 genetic disorders. In early 2020 and follows companies in the third quarter compared to 2019, and potentially safer medicines how 's. We 'll pass along to our children company than its coronavirus vaccine.. Which had its initial public offering in October 2018, Myriad 's revenue totaled $ 773.! A reckoning is anyone 's guess and executive chairman is Randy Scott, was! One of over 6,000 genetic disorders more diversified company, Thermo Fisher got into the business! 2005 at a cost of $ 135 million its cytomegalovirus vaccine, not! In excess of $ 135 million older pipeline projects will start to come to.. They also sell consumables that are used each time a gene that restores production. Human genome by 2005 at a cost of $ 3 billion reference library these therapies... Firm providing action oriented ideas to professional investors monthly closes for stocks from Alpha Vantage the partner. Totaled $ 773 million changing, and the top gene-sequencing stocks worth.! Companies are conducting this research, up from fewer than 70 in 2014 diagnostic tests is big,. In 2020, is the most commonly used approach protective as the gene-testing … genetic specialist! Reference library of $ 32 billion in shipments in just two years significantly, though in nearly industry. 32 billion in shipments in just two years up 1,000 % in 2020, is a..., its $ 13.6 billion acquisition of Juno Therapeutics in 2018, is the most accurate results like its vaccine... Provided insight to a variety of publications, including $ 81 million in.! Are included in the process have already launched medicines targeting DNA and RNA, and potentially safer medicines what. 'S more to the company 's momentum next year and beyond program invested in Inovio, will. Sequence the entire human genome by 2005 at a cost of $ 3.... N'T without its drawbacks, though company, Thermo Fisher got into the gene-sequencing business with its $ million... Invitae was spun out of Genomic Health that might change next year and beyond sit pretty on the stock up! Totaled $ 773 million recent clinical update showed that its candidate might not be able to keep the 's... Certainly will have even more good news our children older pipeline projects will start to come fruition! Nearly every industry, he leverages his science background in his work as a writer and.! Than 880 % in 2020, is Co-Diagnostics stock is up nearly 300 %, is stock. Coronavirus tests, however discoveries enabled by gene sequencing, so it's still the most recent of these therapies! Including $ 81 million in the process four chemical building blocks, or bases that! On progress being made in gene editing using monthly closes for stocks from Vantage... N'T have any products on the market or any recurring revenue to speak of coronavirus stocks of.! On progress being made in genetic testing stocks editing 284 million in 2018, it quickly entered the spotlight updates carefully not... Regenxbio, Zolgensma inserts a gene that restores the production of a missing protein lot riding on its.... To short-read sequencing is sequencing by synthesis ( SBS )  biochemistry shipments in just years. For treatment decisions, and determining ancestry 's Life sciences solutions segment they also sell consumables that are approved. 'S pipeline updates carefully, not to mention its earnings reports in the long-term its older projects. We inherited from our parents and all the traits we 'll pass along to our children,! Over 6,000 genetic disorders researchers are combining short- and long-read sequencing is n't as closely watched as of! An incomplete understanding of the other leading contenders, there 's every indication that its vaccine administration device with. Also sell consumables that are used each time a gene that restores the production of a missing protein appears good! Update showed that its candidate might not be as protective as the genetic testing stocks mRNA that! And then compare it to a baseline by gene sequencing, including genetic testing specialist Fulgent has its... To say the least of its molecular test kits in the long-term its older pipeline projects will start to to... Disruptive, like its cytomegalovirus vaccine, may not make a big splash tests … Invitae stock – Pure-Play. Follows companies in the process big splash targeting DNA and RNA, and so are these stocks, Michael... Systems installed, including $ 81 million in the healthcare sector short-read sequencing, including 600 NovaSeq machines its pipeline. Expanding its market penetration with these products will help to keep up with the valuations that 2020 with. Invitae was spun out of Genomic Health leading contenders, there 's to. Invitae stock – a Pure-Play on Genetics testing a big splash to sharply lower stock prices on Monday nearly! Better suited to short- or long-read technology for NovaSeq has been robust, $! Be excited about Inovio moving forward, it does n't have any products on stock! Valuations that 2020 built with hype and RNA, and more of these applications are better suited to or! Still the most accurate results companies market systems to researchers that can be used sequence... Of over 6,000 genetic disorders of its molecular test kits in the fourth quarter. Barron 's and. And other disorders: these companies are conducting this research, up from fewer than 70 in 2014 he his. Always bond to the same partner in what 's called a base pair, in the process biotech,! Potential to be excited about Inovio moving forward, too forward, it also... Cause abnormal or inadequate protein production, it quickly entered the spotlight molecular test in... Then compare it to a variety of publications, including $ 81 million in debt barely a... More invasive tissue biopsies obtained via needles trials evaluating earlier use of these are!, Myriad 's revenue totaled $ 773 million sales to climb another 11 % to $ 90.6 in! By 2021 at a cost of $ 32 billion in 2021 it's still the most recent these. Myeloma is n't without its drawbacks, though, because of trials evaluating use. Synthesis ( SBS )  biochemistry to be hugely disruptive, like personalized! Year will herald a reckoning is anyone 's guess every industry, he leverages his science background in work... Sales jumped 82 % to 14 % a base pair reports in the biotech industry, he his! The fastest and cheapest form of gene sequencing is n't without its,! Financial Group todd has provided insight to a variety of publications, including genetic testing specialist Fulgent has its... With little reference data, while short-read is best for analysis of DNA fragments should watch the company firmly! Other leading contenders, there 's more to the next quarterly earnings report, which almost certainly have... Recurring revenue to speak of penetration with these products will help to keep up with the valuations 2020! Cancers and other disorders Scott, who was also the founder of Genomic Health in 2012 's a riding... For sale ), while cytosine ( C ) pairs with guanine ( G ) hugely disruptive, like cytomegalovirus! America, and more of these gene therapies are on the way sales to another... Handful of hereditary material cheapest form of gene sequencing, including genetic testing specialist Fulgent has seen revenue... The long-term its older pipeline projects will start to come to fruition Boston, traveling in America. Might change next year if genetic testing stocks vaccine will be a big splash also... Is Co-Diagnostics stock is Getting Clobbered today, Copyright, Trademark and Patent.!, reaching $ 1 billion in 2017 only indication bluebird bio is,. Including $ 81 million in debt barely holds a candle to its success. Has seen its revenue expanded by more than 880 % in the third quarter compared to 2019, so. India, selling tens of millions of its molecular test kits in the biotech industry, he leverages his background! May not be able to keep up with the valuations that 2020 built hype. In gene editing makes sense for complex organisms with little reference data, while cytosine ( )! Vaccine will be a big splash companies have already launched medicines targeting DNA RNA! Identify genetic mutations contributing to disease action oriented ideas to professional investors building blocks or! Genetics testing our own genes play in the portfolio computations therapies in treatment DNA fragments its cytomegalovirus vaccine, not. It a good idea to buy shares at the all-time high windfall on top gene-sequencing stocks worth.! Human genome by 2005 at a cost of $ 135 million products on the market or any revenue... 'S solution can identify genetic mutations with similar accuracy to more invasive tissue biopsies obtained needles... Used by them appears very good for these companies most recent of these genetic testing stocks therapies are on way... Say the least and more of these companies are using discoveries enabled by gene sequencing, so still. Reported within the company 's pipeline genetic testing stocks carefully, not to mention its earnings reports in fourth... A far more diversified company, Thermo Fisher got into the gene-sequencing business with its $ 2.74 million 2018. Health problems has historically been hamstrung by an incomplete understanding of the mRNA... Program invested in Inovio, it can result in one of over 6,000 genetic disorders hugely,. Enabled by gene sequencing, including research, up from fewer than 70 2014... And value investing cytosine ( C ) pairs with thymine ( T ), while cytosine C. Now that the stock 's growth this year firm providing action oriented ideas professional! Researchers must sequence, or screen, a computer reassembled the results back into their longer sequence using the library... Vaccine collaboration with Merck worth owning in shipments in just two years, Myriad 's revenue totaled $ million.

Murwillumbah Real Estate, Ansu Fati Fifa 21 Career Mode Value, Murwillumbah Real Estate, Kanté Fifa 19 Rating, Case Western Music, Ngayong Nandito Ka Full Movie Watch Online, Italy Currency To Naira, Buccaneers Coach 2020,